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Background: Transapical transcatheter aortic valve implantation (TA-AVI) has
become a well accepted alternative treatment for patients with severe aortic stenosis
and high surgical risk. While ﬁrst generation devices yield acceptable clinical and
hemodynamic outcomes, second generation devices have become available, poten-
tially facilitating implantation procedures and improving postoperative outcome.
Methods: From March 2008 through December 2012, a total of 420 patients were
treated by TA-AVI at our center. Of these, 142 patients (80.36.1 years, 60% male,
19.39.8% logEuroSCORE I) received second generation devices for TA-AVI (TA-
AVI2nd; JenaValve n¼63, Symetis Acurate n¼38, Medtronic Engager n¼41). Data
were prospectively entered into a dedicated database and retrospectively analyzed.
Results: In 142 patients after TA-AVI2nd, procedure time, ﬂuoroscopy time and amount
of contrast usedwere 92.249.1min, 7.44.1min and 168.382.4ml respectively.Acute
device success was achieved in 97.2% (138/142). 30-day mortality was 4.2% (6/142),
periprocedural stroke rate was 1.4% (2/142). The degree of paravalvular leakage at
discharge was 0.50.6 with PVL  grade 2 in four patients only (2.8%). At discharge,
transvalvular gradients were mean/max 10.84.1 / 21.47.6 mmHg respectively.
Conclusions: TA-AVI2nd using JenaValve, Symetis Acurate and Medtronic Engager
devices yield excellent acute clinical and hemodynamic outcomes in this early single-
center experience. Ease of implantability and good functional outcome with low rates of
relevant PVL appear to be the most obvious improvements compared to ﬁrst generation
devices. TA-AVI2nd devices may eventually lead to a patient-centered tailor-made
approach to transcatheter treatment of aortic stenosis in high-risk patients. Before
recommendations on which device is best suited for which patient can be made, expe-
rience in larger patient numbers and with longer follow-up will have to be awaited.
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Background: In transcatheter aortic valve implantation (TAVI), conduction abnor-
malities (CA) may complicate the peri- and postoperative patient management and
outcome. Herein, both atrio-ventricular and intra-ventricular CA occur, and trigger
permanent pacemaker (PP) implantation in some patients. However, within the time
course of postinterventional prosthetic healing, CA may in part be reversible.
Methods: Out of 121 patients that underwent TAVI, a total of 69 patients were
identiﬁed with no baseline ventricular conduction disturbances or previous PP
implantation (n¼41 Medtronic CoreValve, n¼28 Edwards Sapien TAVI prostheses).
12-led electrocardiograms were recorded before TAVI, on day one and before hospital
discharge, as well as one month and 6 months after the procedure.
Results: At day 1 following TAVI, new-onset left bundle branch block (LBBB) was
observed in 36 (52%) and right bundle branch block (RBBB) in 2 (3%) of the patient
collective, and 2 (3%) patients had undergone PP implantation directly after the TAVI
procedure for complete atrioventricular block (AVB). Accordingly, mean QRS
duration increased from 98,3  10,8 ms to 140,2  30,9 ms (p<0.0001) on day 1.
New-onset LBB completely resolved during in-hospital stay in 4 (11%) of patients,
and mean QRS duration decreased to 123,9  28,7 ms at discharge, 109,0  26,2 ms
at 30 days, and 104,7  10,9 ms at 6 months. New-onset atrial ﬁbrillation (AF) was
seen in 11 (16%) of patients. The mean PR interval in those patients without AF at
baseline or 1d follow-up (n¼48) increased from 191,0  51,2 ms to 246,7  96,3 ms
(p¼0,004). Thereafter, PR interval in those patients that were neither paced nor
developed AF decreased to 210,6  79,0 ms at hospital discharge, 206,2  48,7 ms at
30 days and 205,3  61,0 ms at 6 months. Since criteria for PP implantation after
TAVI are not standardized, and the present patient cohort includes our center's initial
TAVI patients, the rate of PP implantation was rather high, with 29/68 (43%) patients
receiving a PP within 6 months following TAVI, of whom 27 (93%) underwent PP
implantation during their TAVI hospital stay. Most frequent indications were
complete AVB (46%) and new LBBB (38%).
Conclusions: Atrio-ventricular and intra-ventricular conduction disturbances
frequently occur after TAVI. However, the observed prolongation in PR and QRS
durations in patients that were not considered for PP implantation apparently resolve –
at least in part – with time following the TAVI procedure.
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Background: With the introduction of the Medtronic CoreValve 31mm prosthesis
(Medtronic Inc., Minneapolis, MN, USA) patients with large aortic annulus have become
eligible for transcatheter aortic valve implantation (TAVI). So far, no studies regarding
the clinical experiences with this prosthesis have been published. The aim of this study is
to evaluate the feasibility, efﬁcacy and safety of TAVI using the Medtronic CoreValve
31mm prosthesis in patients with severe aortic valve stenosis and large aortic annulus.
Methods: Five institutions in the Netherlands and Italy participated in a retrospective
multi-center registry. Clinical, procedural and imaging data of patients treated with the
CoreValve 31mm were retrospectively collected in accordance with the VARC-2 criteria.
Results: Between August 2011 and November 2012, 47 patients (44 males, mean age
77.6  8.9 years) received the CoreValve 31mm prosthesis for severe aortic stenosis.
Device success (no all-cause 30-day mortality and correct positioning of a single valve
with intended performance) was achieved in 31 patients (66.0%). Reasons for not ful-
ﬁlling the device success criteria were: in-hospital mortality in 2 patients (4.2%),
signiﬁcant prosthetic aortic regurgitation in 4 patients (8.5%) and second valve implan-
tation in 10 patients (21.3%) (8 cases of malpositioning with high-grade aortic regurgi-
tation, 1 acute and 1 delayed valve dislocation). Peak and mean transaortic gradients
decreased signiﬁcantly (p < 0.001). The rate of pacemaker implantations was 31.9%.
Conclusions: In this retrospective multi-center registry, transcatheter treatment of
severe aortic valve stenosis with the Medtronic CoreValve 31mm device appeared to
be challenging, even in experienced hands. If the prosthesis is properly implanted, it
offers adequate valve hemodynamics and proper functioning.
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Background: Assessment of frailty complements traditional risk assessment in high-
risk older adults with aortic stenosis (AS). Subjective frailty assessment is widely
used, but its associations with objective markers of frailty are poorly characterized.
Methods: Frailty was subjectively assessed by an interventional cardiologist or
physician assistant in high risk older adults with AS in the valve clinic at our center. A
trained coordinator then objectively assessed frailty by measuring 15 foot walk time,
grip strength, independence in activities of daily living (ADL), and collecting serum
albumin as a marker of malnutrition. Markers of frailty were compared between those
considered frail and not frail by the subjective assessment.
Results: Among 92 patients, 28 (30%) were considered frail by subjective assessment.
Those considered frail were older (866 vs 846 yrs, p¼0.06) with higher STS scores
(9.84.4 vs 7.23.0, p¼0.009), but did not differ in gender (64% vs 50% female, p¼0.2),
or BMI (25.67.3 vs 25.54.2, p¼0.97). The frail group had more ADL dependence (79
vs 36%, p¼0.0002), slower gait speed (0.370.16 vs 0.670.17 m/s, p<0.0001), lower
grip strength (women: 12.64.9 vs 16.34.9 kg, p¼0.01, men: 18.07.9 vs 26.5 kg,
p¼0.01), and lower albumin (3.60.48 vs 4.00.48 g/dL, p<0.0001).
Conclusions: Among older adults with AS evaluated in a specialized valve center,
those considered frail by subjective assessment were slower, weaker, more
malnourished, and had more ADL impairment. Future studies will be needed to
determine the optimal frailty assessment to predict outcomes in older adults with AS.1, 2013 j TCT Abstracts/POSTER/Aortic Valve Disease and Treatment
